Related Tags >> Eli Lilly Daiichi Sankyo FDA FDA approval

prasugrel News

Most Popular prasugrel Story

Lilly submits prasugrel NDA

January 4, 2008 — 7:59am ET

Eli Lilly and Daiichi Sankyo have submitted the much-watched drug prasugrel to the FDA. The drug--an oral antiplatelet agent--is poised to take on the blockbuster Plavix. Read more...

prasugrel Press Releases

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
FDA Continues to Review Prasugrel New Drug Application

Latest Headlines

Doctor demands halt to FDA review of Lilly's prasugrel
June 3, 2009
FDA erred in excluding expert from review
February 24, 2009
Lilly gets approval for blockbuster Prasugrel
February 23, 2009
Lilly gets unanimous vote in favor of prasugrel
February 4, 2009
Prasugrel vote will signal FDA's risk/benefit stance
February 2, 2009
Daiichi, Lilly: still no word on prasugrel
October 17, 2008
FDA again delays prasugrel decision
September 29, 2008
Deadline clock running on Lilly's next big blockbuster
September 22, 2008
Biopharma sees tougher FDA approval process
June 30, 2008
FDA delays review of Eli Lilly’s would-be blockbuster
June 24, 2008
Prasugrel gets priority review
February 22, 2008
Lilly submits prasugrel NDA
January 4, 2008
Lilly drug outperforms Plavix, but there's a catch
November 5, 2007
Lilly suspends dosing in crucial drug trial
October 25, 2007

Paid Research Reports

More Research Reports >>